http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105816421-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1075 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4985 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4985 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P33-12 |
| filingDate | 2016-05-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105816421-B |
| titleOfInvention | A kind of praziquantel nano-emulsion in-situ gel and its preparation method and application for prevention and cure of schistosomiasis |
| abstract | The praziquantel nano-emulsion in-situ gel and its preparation method and application that the invention discloses a kind of for prevention and cure of schistosomiasis, it is by the modern nanometer formulation technology of application, hydrophobic praziquantel is initially formed the O/W type nano-emulsion that energy and water are mixed with arbitrary proportion, it is highly dispersed in hydrophilic reversed gel again, the water type injection that transparent and homogeneous, stability are good, syringeability is good and are suitable for viscosity is made.Beneficial effects of the present invention: experiment in vitro shows that praziquantel nano-emulsion in-situ gel provided by the invention has apparent slow release characteristic, so as to extend its function of preventing and treating schistosomiasis in animals, simultaneously, the problem of this pharmaceutical composition is all made of medicinal degradation material, and irritation and injection site lesion is not present. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021260062-A1 |
| priorityDate | 2016-05-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 39.